1. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organisation; 2002.
2. USA General Accounting Office. FDA drug review—post approval risks 1976–1985. 26 April 1990. GAO IPEMD.90. Available at: http://www.gao.gov/products/PEMD-90-15 . Accessed 24 May 2015.
3. Patel DN, Low WL, Tan LL, Tan MM, Zhang Q, Low MY, et al. Adverse events associated with the use of complementary medicine and health supplements: an analysis of reports in the Singapore pharmacovigilance database from 1998 to 2009. Clin Toxicol (Phila). 2012;50(6):481–9.
4. Teo D, Ng P, Tan SH, Lim A, Toh D, Chan SY, et al. Drug-induced liver injury associated with complementary and alternative medicine: a review of adverse event reports in an Asian community from 2009 to 2014. BMC Complement Altern Med. 2016;16(1):192.
5. Council for International Organizations of Medical Sciences. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII on application of signal detection in pharmacovigilance. Geneva: Council for International Organizations of Medical Sciences; 2010.